Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells

[1]  Vassiliki Tzelepi,et al.  Therapeutic targeting of the prostate cancer microenvironment , 2010, Nature Reviews Urology.

[2]  D. Grandér,et al.  Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. , 2010, International journal of oncology.

[3]  Kristian Pietras,et al.  Hallmarks of cancer: interactions with the tumor stroma. , 2010, Experimental cell research.

[4]  D. Grandér,et al.  Autophagy: cancer therapy's friend or foe? , 2010, Future medicinal chemistry.

[5]  E. Haura,et al.  Src kinases as therapeutic targets for cancer , 2009, Nature Reviews Clinical Oncology.

[6]  E. Morselli,et al.  Anti- and pro-tumor functions of autophagy. , 2009, Biochimica et biophysica acta.

[7]  S. Cook,et al.  Tumour cell survival signalling by the ERK1/2 pathway , 2009, Cell Death and Differentiation.

[8]  David Cameron,et al.  A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer , 2009, Nature Medicine.

[9]  M. Hung,et al.  Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. , 2008, Cancer research.

[10]  S. Steinberg,et al.  A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer , 2008, Clinical Cancer Research.

[11]  L. Seymour,et al.  A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  D. Strumberg,et al.  A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV , 2007, British Journal of Cancer.

[13]  J. Squire,et al.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome , 2007, British Journal of Cancer.

[14]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.

[15]  A. Papatsoris,et al.  The power and promise of “rewiring” the mitogen-activated protein kinase network in prostate cancer therapeutics , 2007, Molecular Cancer Therapeutics.

[16]  H. Kung,et al.  Nonreceptor tyrosine kinases in prostate cancer. , 2007, Neoplasia.

[17]  H. Kantarjian,et al.  The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-α-expressing cells through caspase-3-mediated cleavage of Mcl-1 , 2007, Leukemia.

[18]  S. Wilhelm,et al.  Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.

[19]  Paulo A. S. Nuin,et al.  Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. , 2006, Cancer Genetics and Cytogenetics.

[20]  S. de Vos,et al.  FOXO‐dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  D. Gioeli.  Signal transduction in prostate cancer progression. , 2005, Clinical science.

[22]  P. Auberger,et al.  Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis , 2004, Oncogene.

[23]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[24]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[25]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[26]  D. Grandér,et al.  Interferon-α-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax , 2003, Oncogene.

[27]  D. Grandér,et al.  Activation of Bak, Bax, and BH3-only Proteins in the Apoptotic Response to Doxorubicin* , 2002, The Journal of Biological Chemistry.

[28]  D. George.  Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. , 2002, Urology.

[29]  G. Ayala,et al.  Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  G. Kroemer,et al.  Quantitation of mitochondrial alterations associated with apoptosis. , 2002, Journal of immunological methods.

[31]  J E Paciga,et al.  AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. , 2001, The American journal of pathology.

[32]  Takeshi Noda,et al.  LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing , 2000, The EMBO journal.

[33]  S R Datta,et al.  14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. , 2000, Molecular cell.

[34]  K. Moelling,et al.  Phosphorylation and regulation of Raf by Akt (protein kinase B). , 1999, Science.

[35]  Y. Takano,et al.  Prognostic significance of Ki‐67, p53, and Bcl‐2 expression in prostate cancer patients with lymph node metastases: A retrospective immunohistochemical analysis , 1998, Pathology international.

[36]  H. Kung,et al.  A tyrosine kinase profile of prostate carcinoma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  H. Moch,et al.  Prognostic significance of Bcl-2 in clinically localized prostate cancer. , 1996, The American journal of pathology.